Use access key #2 to skip to page content.
$1.00 -0.30 (-23.08%)
10/6/2008 4:00 PM

OXiGENE, Inc. (OXGN)

CAPS Rating:
No stars

A biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

OXGN doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

42 Outperforms
2 Underperforms
 

All-Stars

5 Outperforms
1 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on OXGN are also bullish on:

Members bearish on OXGN are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (295)
Suggest a tag

OXiGENE, Inc. At A Glance

Current Price: $1.00
Last Trade Time: 10/6/2008 4:00 PM
Open: $0.00
Previous Close: $1.30
Daily Range: $0.93 - $1.25
52-Week Range: $1.05 - $3.79
Volume: 86,244
Market Cap: $37.93M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

OXGN VS S&P 500 (SPY)

OXGN 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for OXGN

More Headlines...

Top Bull Pitch

Recs

2

OXiGENE, Inc. (OXGN)

Avatar jwfoster (99.44) Submitted: 5/05/07 10:34 PM

I am not smart enough to figure out which drugs will be good or bad. What will pass phase III trials, etc. But, what I do know is that when a biotech stock has tons of insiders who know the drug business buying up shares like crazy and have a lung cancer product that they can charge whatever they ...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 7 :   1 2 Next »

Recs

0

 (OXGN)

Avatar BullCoder (< 20) Submitted: 10/01/07 11:02 AM : Outperform Start Price: $3.55 OXGN Score: -40.07

Technology to attack cancer tumors by quickly reducing blood supply is fascinating, and the company has attracted serious players for management. I suggest listening to their recent UBS Global presentation (about 30 minutes) through this link on their web site:
http://www.oxigene.com/press/calendar.asp

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (OXGN)

Avatar suave1007 (< 20) Submitted: 8/14/07 6:29 PM : Outperform Start Price: $3.57 OXGN Score: -45.36

Science: Destroys in minutes ALL blood vessels of tumor!while preserving ALL other healthy cells!! NO side effects:
http://www.wsw.com/webcast/rrshq10/oxgn/3__Slide16.JPG
OXGN SAFETY:Lazard pres.

Seasoned and creditentialled Mgt Team under Dr. Richard Chin who guided two of Genentechs current blockbusters: Avastin & Lucentis. In his 3rd month as CEO downsized co 33% and focused strategy of timely executions.

Poised for Success is OXGN's Mantra.

$4+mln of open mkt purchases by mgt team! $65K during Aug 5-10 by newest director Fickling.

Indeed rare to find a $100 mln Mkt Cap. oncology play IN Phase THREE!

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (OXGN)

Avatar jwfoster (99.44) Submitted: 5/05/07 10:34 PM : Outperform Start Price: $4.74 OXGN Score: -49.48

I am not smart enough to figure out which drugs will be good or bad. What will pass phase III trials, etc. But, what I do know is that when a biotech stock has tons of insiders who know the drug business buying up shares like crazy and have a lung cancer product that they can charge whatever they would want, it is worthy of buying.

This is not just a caps pick but, one of my larger personal holdings.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (OXGN)

Avatar oj1480 (< 20) Submitted: 2/05/07 10:50 AM : Outperform Start Price: $4.43 OXGN Score: -49.80

i heard good news about this one.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (OXGN)

Avatar TechnicalTommy (< 20) Submitted: 1/17/07 4:29 AM : Outperform Start Price: $4.71 OXGN Score: -52.08

Favorable news from pipeline in December. Things have finally settled down now.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 7 :   1 2 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackStifel 90.77 03/06/07 Outperform NS $4.07-75.43%-25.10%-50.33

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners